The supplied CJC-1295 + Ipamorelin certificate names a blend of Modified GRF (1–29) and ipamorelin. Its 10 mg total label consists of 5 mg of each component; those label amounts are separate from the measured results.
The two components in the supplied report
The report for lot BLD-29-E96 uses Modified GRF (1–29) for the component marketed as CJC-1295 without DAC. The document gives a separate declared mass and measured assay result for each component.Supplied Modified GRF (1–29) + Ipamorelin report — lot BLD-29-E96 (opens in a new tab)
| Component | Labelled amount | Reported measured content |
|---|---|---|
| Modified GRF (1–29) | 5 mg | 5.00 mg |
| Ipamorelin | 5 mg | 5.01 mg |
The 10 mg label is the combined labelled content. The report identifies a mixture of two peptides, so a single peptide sequence, molecular formula, molecular weight or CAS number is not assigned to the blend here.Supplied Modified GRF (1–29) + Ipamorelin report — lot BLD-29-E96 (opens in a new tab)
Keep component identities explicit
| Component | Structural record |
|---|---|
| Modified GRF (1–29) | Named in the blend report; the separate supplied report describes a 29-residue amidated peptide without printing its full sequence |
| Ipamorelin | Published sequence Aib–His–D-2-Nal–D-Phe–Lys–NH2; the blend report does not print it |
Use the component identity guides for source-qualified reference fields. A name shared with another CJC-related structure is not enough to identify the first component; the report’s Modified GRF wording should remain attached to the blend record.Supplied Modified GRF (1–29) + Ipamorelin report — lot BLD-29-E96 (opens in a new tab)Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
Combined purity and individual content
The report describes multiplex LC-MS confirmation of the declared components and separate assays against qualified references. Its 99.38% peptide-related chromatographic purity concerns resolved peptide-related substances. The document explicitly distinguishes that value from the proportion of either component.Supplied Modified GRF (1–29) + Ipamorelin report — lot BLD-29-E96 (opens in a new tab)
Product and certificate documents
Sources and further detail
- Supplied Modified GRF (1–29) + Ipamorelin report — lot BLD-29-E96 (opens in a new tab)
Supplied report: identity wording and analytical fields. Results concern the named sample and lot; this is document transcription, not independent authentication.
- Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
Supplied report: identity wording and analytical fields. Results concern the named sample and lot; this is document transcription, not independent authentication.
- Raun et al. (1998) (opens in a new tab)
Sequence and terminal notation only; kept distinct from the blend report.
Identity sources and supplied documents checked for this revision on 3 October 2026. Report transcription is separate from independent authentication. This article has not undergone independent scientific peer review.